Comparison of Ridostin Pro and Poly(I:C) as adjuvant for a cancer neoantigen peptide vaccine

Background. The effectiveness of cancer neoantigen peptide vaccines depends on the presence an adjuvant in their composition. Poly(I:C), a TRL-3 agonist, is used as mouse models vaccines, but has limitations for use humans. Therefore, search new effective adjuvants inclusion composition vaccine relevant. Ridostin Pro domestic drug that contains natural complex sodium salts double-chiral and single-chiral ribonucleic acids, agonist TLR-3, inducer interferon, its antiviral activity shown. In this regard, study interest. Aim. To evaluate ability Poly(I:C) enhance specific T-cell response to synthetic peptides; antitumor efficacy with or adjuvants. Materials methods. Immunogenicity peptides after vaccination evaluated ELISpot. Antitumor effect were model B16-F10 tumor by growth rate survival mice. Results. Vaccination mice contributed appearance immune part vaccine. Pro, both when administered without peptide, inhibits increases life expectancy melanoma B16-F10. Conclusion. promotes formation vaccine, enhances These results confirm may prove be personalized vaccines.